Combination therapy improves efficacy in widespread prostate metastatic disease
Combination therapy improves efficacy in widespread prostate metastatic disease.
Applied Radiology, 50 (6), 38-41.
CASE SUMMARY: A 79-year-old man with prostate cancer previously treated in 1997 with radical prostatectomy and subsequently treated with hormone therapy (ADT, abiraterone), chemotherapy (docetaxel, cabazitaxel), and strontium for metastatic bone disease presented in July 2017 with rising PSA levels. The patient’s PSA levels rose from 764 ug/L on July 4, 2017, to 1,722 ug/L on Sept. 5, 2017, 1,950 ug/L on Sept. 25, 2017, to 2,481 ug/L on Nov.1, 2017, when gallium-68 ( 68Ga) PSMA-11 PET/CT scanning was performed.
contrast agents, imaging, case report